HMGCS2、PPARγ在炎症性肠病患者肠黏膜的表达活性及临床意义  

Expression of intestinal mucosal HMGCS2, PPAR γ in patients with inflammatory bowel disease and their clinical significance

作　　者：周三喜[1] 赵芯梅[1] 吕超蓝[1] 伦伟健[1] 智发朝[1] 

机构地区：[1]南方医科大学南方医院消化科,510515

出　　处：《现代消化及介入诊疗》2012年第6期309-312,共4页Modern Interventional Diagnosis and Treatment in Gastroenterology

摘　　要：目的观察HMGCS2、PPARγ在溃疡性结肠炎(UC)及克隆恩病(CD)中的表达情况,通过对UC、CD及健康对照组比较,分析其在IBD发生发展的分子学基础。方法收集南方医院消化科病房及门诊2010年2月～2011年1月间所行常规全结肠镜检查后内镜下活检的73例UC、42例CD、89例健康对照者的肠黏膜。比较UC组和CD组之间一般临床特点和检查资料的差异。结果 73例UC中发生在直肠的28例(38.4%),发生在直乙状结肠9例(12.3%),发生在左半结肠的11例(15.1%),发生在全结肠的25例(34.2%);42例CD患者有29例发生在回末和小肠(69.0%)。HMGCS2、PPARγ在73例UC患者肠黏膜中阳性表达分别为48例(65.8%)和36例(49.3%);在42例CD患者肠黏膜中阳性表达分别为37例(88.1%)和30例(71.4%);在89例正常对照组肠黏膜阳性表达占82例(92.1%)和66例(74.2%)。结论 HMGCS2、PPARγ在UC、CD、健康对照组均有表达,在UC患者肠黏膜明显下调,而在CD和健康者无明显变化。Objective To observe the expression of HMGCS2 and PPARγ in ulcerative colitis （UC） and colon＇s disease （CD）. Methods Seventy three UC patients and 42 CD patients diagnosed by colonoscopy and biopsy were enrolled in this study from February 2010 to January 2011. Eighty nine healthy volunteers were as control. Result In 73 UC patients, the lesions located at the rectum in 28 patients （38.4%）, at the sigmoid colon in 9 patients （12.3%）, at the left-sided colon in 11 patients （15.1%）, the whole colon involved in 25 patients （34.2%）. In 42 CD patients, the lesions located at the terminal ileum and small intestine in 29 patients （69%）. The positive expression of HMGCS2, PPARγ in intestinal mucosa was found in 48 （65.8%） and 36 （49.3%） UC patients and in 37 （88.1%） and 30 （71.4%） 42 CD patients. In control group, the positive expression of HMGCS2, PPARγ in intestinal mucosa was 82 （92.1%） and 66 cases （74.2%）, respectively. Conclusion HMGCS2 and PPARγ were expressed in UC, CD, and healthy subjects. However, they were significantly down-regulated only in the intestinal mucosa of patients with UC.

关 键 词：HMGCS2、PPARγ 炎症性结肠病 克罗恩病 

分 类 号：R589[医药卫生—内分泌]